Efalizumab for resistant moderate-to-severe plaque.(PIPELINE PREVIEWS)(Clinical report): An article from: Journal of Drugs in Dermatology

This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on February 1, 2010. The length of the article is 343 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Efalizumab for resistant moderate-to-severe plaque.(PIPELINE PREVIEWS)(Clinical report)
Author: Unavailable
Publication:Journal of Drugs in Dermatology (Magazine/Journal)
Date: February 1, 2010
Publisher: Journal of Drugs in Dermatology, Inc.
Volume: 9 Issue: 2 Page: 183(1)

Article Type: Clinical report

Distributed by Gale, a part of Cengage Learning